Secretion of biologically active murine interleukin-10 by Lactococcus lactis.
about
Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine ModelsHeterologous Expression and Delivery of Biologically Active Exendin-4 by Lactobacillus paracasei L14Selection of single-chain antibodies against the VP8* subunit of rotavirus VP4 outer capsid protein and their expression in Lactobacillus casei.Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation.Novel xylan-controlled delivery of therapeutic proteins to inflamed colon by the human anaerobic commensal bacteriumProbiotics and the management of inflammatory bowel disease.Delivery of therapeutic proteins to the mucosa using genetically modified microflora.Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease.Probiotics: properties, examples, and specific applications.Therapeutic drug delivery by genetically modified Lactococcus lactis.Utilization of D-ribitol by Lactobacillus casei BL23 requires a mannose-type phosphotransferase system and three catabolic enzymesMalic enzyme and malolactic enzyme pathways are functionally linked but independently regulated in Lactobacillus casei BL23Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis.Accumulation of polyphosphate in Lactobacillus spp. and its involvement in stress resistance.Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases.Lactobacillus delivery of bioactive interleukin-22.Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option.Living biointerfaces based on non-pathogenic bacteria to direct cell differentiation.Functional living biointerphases.Improving health from the inside: Use of engineered intestinal microorganisms as in situ cytokine delivery system.Nisin-inducible secretion of a biologically active single-chain insulin analog by Lactococcus lactis NZ9000.Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis.Identification and characterization of the novel LysM domain-containing surface protein Sep from Lactobacillus fermentum BR11 and its use as a peptide fusion partner in Lactobacillus and Lactococcus.Regulation of Lactobacillus casei sorbitol utilization genes requires DNA-binding transcriptional activator GutR and the conserved protein GutM.Influence of two-component signal transduction systems of Lactobacillus casei BL23 on tolerance to stress conditionsRequirement of the Lactobacillus casei MaeKR two-component system for L-malic acid utilization via a malic enzyme pathway.Evasin-displaying lactic acid bacteria bind different chemokines and neutralize CXCL8 production in Caco-2 cells.Coproduction of colicin V and lactic acid bacteria bacteriocins in lactococci and enterococci strains of biotechnological interest.Use of anaerobic green fluorescent protein versus green fluorescent protein as reporter in lactic acid bacteria.Trimming of two major type 1 diabetes driving antigens, GAD65 and IA-2, allows for successful expression in Lactococcus lactis.A Recombinant Probiotic, Lactobacillus casei, Expressing the Clostridium perfringens α-toxoid, as an Orally Vaccine Candidate Against Gas Gangrene and Necrotic Enteritis.Oral immunization of mice with Lactococcus lactis expressing the rotavirus VP8* proteinScreening and construction of probiotic strains with enhanced protective properties against intestinal disorders
P2860
Q28083627-F37172A3-9BDC-424A-B415-351DF065D0E5Q28552845-98662BB6-BFA2-4747-AA7B-BFF1D29FF685Q31125835-BC773DB0-7EFD-47D9-93EC-339EA23F4998Q33578069-95E2ADBD-828A-4AE5-8267-F446630EC7FDQ34344893-DD65D6A5-BADE-4943-99B1-B49E30463A77Q35854517-238A51DB-60C6-4315-9940-C32A54539DC5Q36316890-3F42AEE5-8548-4718-A6CE-CC7234EFAD36Q36549836-1B969584-774E-450E-B885-216DF701ED39Q36629073-73765D28-DFA4-4A83-9C8A-659E1E9844F5Q36631447-A0C793B5-F024-46BD-8366-EE5FC4AD5E21Q36911554-9F3E5E34-0ECE-4C8C-9AD3-9EEF9C00CD3AQ37123683-92D406AF-288A-4A41-BEDE-CA167A5B08B3Q37642861-FC2D8EA3-29D5-4E10-AEE3-6797C203C708Q37643219-515BBF53-37B0-4F48-80F2-46FE672D9600Q38339037-4EE3DFBA-6833-4DA1-B22E-0B744CCEDE6CQ38694409-332EBD8C-21ED-4622-AD38-5219A9F07937Q38827869-E2719737-370D-49E4-AF37-8BF633BD845DQ38971051-F66CA9CE-839A-4474-A6D0-5B7A37137612Q39187508-1FF4991E-ADC4-4972-89CA-B38AA7FDECE3Q39251357-CF444636-757F-40E8-B6CE-2D1244A971DBQ39578319-6DDCBB2C-BCA8-4E01-8246-2F72EF31EA6AQ39793093-4735E2A0-9679-4CBE-AE5C-4580DC14EFD2Q40937780-EA916513-6533-4BCD-95F3-3F31D57C31B5Q42100889-8D432EAF-0354-45FB-8AB2-31A6FEBF7811Q42706397-9A5E95F7-FAF0-4179-84C6-89D4C43EFFCDQ42946905-C3FBC76D-6512-4DD1-BF50-72A96B0F8467Q43216438-9FEFE04B-BCD7-4B7C-B54D-7DDF585F8E85Q48162914-62331451-6EB1-4E2F-B2C0-1F607D384751Q48663193-E2F22399-D44F-4C5F-AA74-DC220FDAF732Q51018806-27A9AF66-29ED-4B36-86B6-7AB7A1669B94Q51062689-6D73C86F-7D8B-4630-821D-B39986FBC10AQ57223797-98F47D93-14DD-4307-BD60-4FD90BF6F98BQ57223980-F2E8EF1C-8DB3-4F2D-83D4-0E6A7A8E2EDB
P2860
Secretion of biologically active murine interleukin-10 by Lactococcus lactis.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Secretion of biologically active murine interleukin-10 by Lactococcus lactis.
@en
Secretion of biologically active murine interleukin-10 by Lactococcus lactis.
@nl
type
label
Secretion of biologically active murine interleukin-10 by Lactococcus lactis.
@en
Secretion of biologically active murine interleukin-10 by Lactococcus lactis.
@nl
prefLabel
Secretion of biologically active murine interleukin-10 by Lactococcus lactis.
@en
Secretion of biologically active murine interleukin-10 by Lactococcus lactis.
@nl
P2093
P1476
Secretion of biologically active murine interleukin-10 by Lactococcus lactis.
@en
P2093
Steidler L
Vandekerckhove J
P304
P356
10.1016/S0141-0229(00)00297-0
P577
2000-12-01T00:00:00Z